TearLab Corporation

138 articles about TearLab Corporation

• TearLab® Announces Corporate Name Change to Trukera™ Medical, Positions Company for Further Expansion in Corneal Health

  9/7/2022

  TearLab® Corporation, the global leader in ophthalmic point-of-care diagnostics, announced that it will be expanding its position in corneal health under the new name Trukera™ Medical.

• TearLab Closes Acquisition By Accelmed Partners

  7/9/2020

  TearLab Corporation (TearLab), a leader in diagnostics for dry eye disease (DED), today announced their acquisition by Accelmed Partners II (AP-II). As a newly formed private company, TearLab is now positioned to pursue further devel

• TearLab Announces Acquisition By Accelmed Partners And Related $25 Million Investment

  5/11/2020

  TearLab Corporation, a leader in Ocular Surface Diagnostics, announced it has entered into a definitive agreement pursuant to which Accelmed Partners II will acquire TearLab.

• TearLab Corporation Confirms Merger Discussions

  5/7/2020

  In light of recent market rumors, TearLab Corporation confirmed that TearLab is engaged in advanced discussions regarding a potential business combination whereby TearLab will be acquired at a price per share equal to $0.0586.

• TearLab Resubmits 510(k) for U.S. FDA Clearance of the TearLab Discovery™ MMP-9 Test

  4/22/2020

  TearLab Corporation (OTCQB: TEAR) (“TearLab” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its 510(k) application for the potential clearance of its TearLab Discovery™ MMP-9 Test, the Company’s next-generation in-vitro diagnostic testing system.

• TearLab Corporation Reports Fourth Quarter and Full Year 2019 Financial Results

  3/5/2020

  TearLab Corporation (OTCQB: TEAR) (“TearLab” or the “Company”) today reported its consolidated financial results for the fourth quarter and twelve months ended December 31, 2019

• TearLab Corporation Reports Third Quarter 2019 Financial Results

  11/7/2019

  TearLab Corporation reported its consolidated financial results for the third quarter ended September 30, 2019.

• TearLab Submits 510(k) for U.S. FDA Clearance of TearLab Discovery Platform

  1/4/2018

  TearLab Discovery will also be capable of performing the Company’s current FDA cleared tear osmolarity test.

• 

  TearLab to Cut More Jobs

  12/27/2017

  TearLab did not report exactly how many employees it will let go

• TearLab Prices $3M Registered Direct Offering

  12/6/2017

  Each unit consists of one share of TearLab common stock.

• TearLab Launches Registered Direct Offering

  11/30/2017

  The Company plans to use the proceeds of this offering for general corporate purposes.

• TearLab Corporation Reports Third Quarter and September Year-To-Date 2017 Financial Results

  11/14/2017

  For the three months ended September 30, 2017, TearLab’s net revenues were $6.5 million, compared with $7.2 million for the same period in 2016.

• TearLab Corporation Begins Trading on OTCQB

  11/9/2017

  As previously disclosed, the Company was unable to regain compliance with NASDAQ Listing Rule 5550(b) prior to November 6, 2017.

• 

  TearLab Tweaks Regulatory Strategy for Next-Generation In-Vitro Diagnostics Testing Platform

  10/18/2017

  Company Remains on-track to submit 510(k) application in 2017.

• TearLab Announces Release Of 2018 - 2020 Preliminary Reimbursement Rates

  9/27/2017

• TearLab Receives Nasdaq Listing Extension

  8/31/2017

• TearLab Reports Second Quarter And First Half 2017 Financial Results

  8/15/2017

• TearLab To Release Second Quarter 2017 Financial Results On August 14, 2017

  8/3/2017

• TearLab Announces European Regulatory Clearance For Next-Generation Tearlab Discovery System

  7/21/2017

• TearLab Receives Nasdaq Listing Extension

  6/22/2017